Recommended Apixaban Dosing for NVAF
ELIQUIS (apixaban): Simple dosing for your patients with NVAF*
In the ARISTOTLE clinical trial, the majority of patients were on 5 mg BD (95.3%, n = 8,692/9,120).2†
Freedom from INR monitoring1
No dietary restrictions and the choice to be taken with or without food1
If a dose is missed, take ELIQUIS immediately and then continue with twice-daily intake as before1
Liver function testing should be performed prior to initiating ELIQUIS1
Please click here to access the ELIQUIS Patient Information Leaflet.
BD = Twice Daily
INR = International Normalised Ratio
ISTH = International Society on Thrombosis and Haemostasis
LMWH = Low Molecular Weight Heparin
NVAF = Non-Valvular Atrial Fibrillation
* ELIQUIS should be used with caution in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp.1 ELIQUIS is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp.1 See Summary of Product Characteristics for warnings and precautions in use and other important safety information.
† The ARISTOTLE clinical trial was a randomised, double-blind, double-dummy non-inferiority trial in 18,201 patients. Stroke / systemic embolism was the primary efficacy endpoint and major bleeding was the primary safety endpoint. The primary safety outcome was major bleeding, according to the criteria of the International Society on Thrombosis and Haemostasis (ISTH). Pre-specified hierarchical sequential testing was performed first on stroke / systemic embolism (primary efficacy endpoint) for non-inferiority, then for superiority, then on major bleeding and, finally, on death from any cause (secondary endpoint).2
‡ ELIQUIS is not recommended for patients with creatinine clearance <15 ml/min, or in patients undergoing dialysis.1
References:
- ELIQUIS® (apixaban) Summary of Product Characteristics.
- Granger CB et al. N Engl J Med 2011; 365: 981–992.